



# Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial

Short running title: DEPICT-2: Long-term Efficacy and Safety

Chantal Mathieu<sup>1</sup>, Gottfried Rudofsky<sup>2</sup>, Moshe Phillip<sup>3</sup>, Eiichi Araki<sup>4</sup>, Marcus Lind<sup>5</sup>, Niki Arya<sup>6</sup>, Fredrik Thorén<sup>7</sup>, Markus Florian Scheerer<sup>8\*</sup>, Nayyar Iqbal<sup>6</sup>, Paresh Dandona<sup>9</sup>, on behalf of the DEPICT-2 Investigators<sup>†</sup>

<sup>1</sup>Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium

<sup>2</sup>Endocrinology and Metabolic Diseases, Cantonal Hospital Olten, Olten, Switzerland

<sup>3</sup>Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Tel-Aviv University, Israel

<sup>4</sup>Department of Metabolic Medicine, Kumamoto University, Kumamoto, Japan

<sup>5</sup>Department of Molecular and Clinical Medicine, University of Gothenburg and Department of Medicine, NU-Hospital Group, Sweden

<sup>6</sup>BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

<sup>7</sup>BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

<sup>8</sup>BioPharmaceuticals Medical, AstraZeneca, Wedel, Germany

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.14060

<sup>9</sup>Department of Endocrinology, Kaleida Health, Buffalo NY, USA

\*affiliation at the time the study was conducted

†A complete list of the DEPICT-2 Investigators can be found in the Supplementary Appendix.

Corresponding author: Chantal Mathieu

Address: Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium

Email: [chantal.mathieu@uzleuven.be](mailto:chantal.mathieu@uzleuven.be)

Telephone number: 003216346994

Fax number: 003216346989

**ORCID iD:** 0000-0002-4055-5233. Mathieu2017

Word count (max 3500): 3712

Number of Tables: 3

Number of Figures: 1

## **Abstract (250 words [max 250])**

### **Aims**

To investigate the long-term efficacy and safety of dapagliflozin as an adjunct to adjustable insulin in adults with type 1 diabetes (T1D) and inadequate glycemic control.

### **Materials and Methods**

DEPICT-2 (Dapagliflozin Evaluation in Patients with Inadequately Controlled T1D; NCT02460978) was a placebo-controlled, double-blind, multicenter, Phase III study of adults with T1D (HbA<sub>1c</sub> 7.5–10.5%) randomized (1:1:1) to receive dapagliflozin 5 mg, 10 mg, or placebo. The efficacy and safety of dapagliflozin over 52 weeks were exploratory endpoints in this extension to DEPICT-2.

### **Results**

Of 813 participants randomized, 88.2% completed the study. From baseline to 52 weeks, dapagliflozin 5 and 10 mg were associated with reduction in HbA<sub>1c</sub> (difference [95% CI] vs. placebo: –0.20% [–0.34, –0.06] and –0.25% [–0.38, –0.11], respectively) and adjusted mean percentage change in body weight (difference [95% CI] vs. placebo: –4.42% [–5.19, –3.64], and –4.86% [–5.63, –4.08], respectively). Serious adverse events were reported in the dapagliflozin 5 mg, 10 mg, and placebo groups (32 [11.8%], 19 [7.0%], and 16 [5.9%], respectively). The proportion of hypoglycemic events was similar across groups; severe hypoglycemia was uncommon.

Accepted Article

More participants with events adjudicated as definite diabetic ketoacidosis (DKA) were in the dapagliflozin 5 and 10 mg groups vs. placebo (11 [4.1%], 10 [3.7%] and 1 [0.4%], respectively); the majority of events were mild or moderate in severity and all resolved with treatment.

### **Conclusions**

Dapagliflozin led to long-term reductions in HbA<sub>1c</sub> and body weight in adults with T1D, but increased DKA risk compared with placebo.

Funding: AstraZeneca

Current word count (max 250): 250

Key words: dapagliflozin, DEPICT-2, SGLT2 inhibitor, type 1 diabetes

## Introduction

In type 1 diabetes (T1D), poor glycemic control is associated with an increased risk of microvascular and macrovascular complications.<sup>1</sup> Insulin-independent adjunct therapies could help in achieving glycemic control in people with T1D. Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in Europe at a dose of 5 mg for use as an oral adjunct to adjustable insulin in adults with T1D and a BMI of  $\geq 27$  kg/m<sup>2</sup>, and in Japan (5 mg or up-titrated to 10 mg if needed) regardless of BMI, when insulin alone does not provide adequate glycemic control.<sup>2-4</sup> Sotagliflozin, a combined SGLT1/2 inhibitor, also received approval in Europe for those with T1D and a BMI of  $\geq 27$  kg/m<sup>2</sup>.<sup>5</sup>

The European and Japanese approvals of dapagliflozin in T1D were based on results obtained in the Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1 and -2) Phase III program; FDA approval was not granted based on these same data. The DEPICT-1 and -2 trials had similar designs, but participants were from different geographical regions. In DEPICT-1, participants were randomized at 138 participating sites across 17 countries.<sup>6</sup> The majority of people in DEPICT-1 were of European descent, whereas in DEPICT-2 ~20% were from the Asia-Pacific region (predominantly Japan).<sup>6-8</sup> Daily dapagliflozin 5 and 10 mg administration was associated with reductions in HbA<sub>1c</sub> from baseline to 24 and 52 weeks compared with placebo in DEPICT-1, and from baseline to 24 weeks in DEPICT-2.<sup>8</sup> Secondary efficacy outcomes

including body weight reduction were also improved in the DEPICT studies.

Dapagliflozin was well-tolerated, with no increase in the risk of hypoglycemia compared with placebo, but with a higher incidence of events adjudicated as definite diabetic ketoacidosis (DKA).<sup>6-8</sup> All DKA events resolved with treatment.<sup>8</sup>

Here, we present results of the 52-week DEPICT-2 study, consisting of the 24-week short-term period plus a 28-week extension, which aimed to assess the long-term efficacy and safety of dapagliflozin in people with T1D. Safety data are aggregated for the 56-week study period, including the 4-week follow-up period.

## Materials and Methods

### Study design and procedures

DEPICT-2 (NCT02460978) was a Phase III, randomized, double-blind, three-arm, parallel-group, placebo-controlled trial conducted at 148 participating sites across 13 countries, including Argentina, Belgium, Canada, Chile, Germany, Japan, the Netherlands, Poland, the Russian Federation, Sweden, Switzerland, the United Kingdom, and the United States.<sup>8</sup>

This study was performed in accordance with the Declaration of Helsinki and is consistent with Good Clinical Practice guidelines as defined by the International Council on Harmonization and applicable regulatory requirements. The study was approved by the institutional review boards and independent ethics committees for all participating centers. Written informed consent was obtained for all participants.

In brief, this study comprised an eight-week lead-in period to optimize diabetes management based on individual needs and treatment tolerability, followed by a 24-week, double-blind treatment period; a 28-week, participant- and site-blinded extension phase, during which participants continued to receive their randomized treatment; and a four-week follow-up period.

During the eight-week lead-in period, the variability in blood glucose profiles were assessed and the frequency of hypoglycemic episodes monitored. On completing the lead-in period, participants entered the 24-week, double-blind treatment period and

were randomly assigned (1:1:1) to dapagliflozin 5 mg, dapagliflozin 10 mg, or placebo using an interactive voice response system. Randomization was stratified by current use of continuous glucose monitoring (CGM), method of insulin administration, and baseline HbA<sub>1c</sub>.

Participants completing the 24-week double-blind period continued their assigned medication to Week 52. Throughout the study, insulin dose could be adjusted according to self-monitored blood-glucose readings, local guidance, and individual circumstances. To minimize risk of DKA, reductions in insulin doses of >20% were not recommended.

### **Study participants**

Adults (18–75 years) were eligible for inclusion in DEPICT-2 if they had a diagnosis of T1D with HbA<sub>1c</sub> 7.7–11.0% at screening/enrollment and 7.5–10.5% at randomization; had used insulin for ≥12 months prior to screening; had been receiving at least three insulin injections per day if following a multiple daily injections regimen or were on an insulin pump (continuous subcutaneous insulin infusion) at a dose of ≥0.3 U/kg/day; their method of insulin administration had not changed for ≥3 months; and had a BMI of ≥18.5 kg/m<sup>2</sup>. People with a history of type 2 diabetes (T2D), or previous use of any SGLT2 inhibitor were excluded. Detailed inclusion and exclusion criteria were described previously.<sup>8</sup>

### **Outcome measures**

*Efficacy*



The long-term efficacy of dapagliflozin was exploratory in the 52-week DEPICT-2 study. Efficacy endpoints at 52 weeks included: adjusted mean change from baseline in HbA<sub>1c</sub>, adjusted mean percentage change from baseline in the total daily insulin dose (TDD), adjusted mean percentage change from baseline in body weight, proportion of participants achieving an HbA<sub>1c</sub> reduction  $\geq 0.5\%$  without a severe hypoglycemic event, and adjusted mean change from baseline in fasting plasma glucose (FPG). Adjusted mean change in seated systolic blood pressure (SBP) was assessed only among participants with hypertension at baseline (defined as SBP  $\geq 140$  mmHg and/or diastolic BP  $\geq 90$  mmHg at baseline). Investigators and patients were not masked to adjusted mean change from baseline in HbA<sub>1c</sub> during the 28-week extension.

### *Safety*

Safety assessments included adverse events (AEs), serious AEs (SAEs), physical examination findings, vital signs, laboratory tests, and electrocardiograms. AEs of special interest (AESI) included hypoglycemia, events adjudicated as definite DKA, genital infections, urinary tract infections, volume depletion, fractures, worsening renal function, hypersensitivity, and cardiovascular AEs.

Hypoglycemia was assessed as the proportion of participants with an event and the frequency and severity of the events. Hypoglycemic events were defined according to the American Diabetes Association (ADA) classification criteria.<sup>9</sup> Severe hypoglycemia was defined as an event that resulted in unconsciousness due to hypoglycemia or

requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions to promote neurological recovery.<sup>8</sup>

Participants were advised how to identify potential signs and symptoms of DKA and were provided with blood ketone monitors and instructions for use. Participants recorded home ketone values ( $\beta$ -hydroxybutyrate) and relevant risk factors in a diary, and were advised to contact the study site if their self-measured blood ketone reading was  $\geq 0.6$  mmol/L. Potential events of DKA were identified by the investigator based on symptoms, diagnoses, or home ketone values, as described previously.<sup>8</sup> Queries were also raised by the sponsor based on pre-defined, Medical Dictionary for Regulatory Activities (MedDRA) preferred terms for AEs potentially indicating DKA. An independent, blinded, DKA Adjudication Committee classified all potential events of DKA as definite, possible, or unlikely DKA. Definite DKA was defined using the ADA consensus criteria and included laboratory-confirmed acidosis (pH  $< 7.3$  and/or bicarbonate  $< 18$  mEq/L), signs and symptoms of DKA were part of a well-documented diagnosis but were not explicitly required.<sup>8,10,11</sup> To avoid missing any potential euglycemic DKA events, glucose was not part of the diagnostic criteria. There were no adjudication criteria for possible and unlikely DKA events as these were not explicitly defined.

## Statistical analysis

Determination of sample size, randomization schedule, and stratification factors have been described previously.<sup>8</sup> Efficacy analyses were performed on all participants in the full analysis set (randomized patients who received  $\geq 1$  dose of study medication) who had baseline and any post-baseline assessment. Analyses on the full analysis set are based on the randomized treatment. Analytical methods for efficacy outcomes in the 24-week treatment period have been reported previously.<sup>8</sup> For all efficacy outcomes, adjusted mean (SE) change or adjusted mean percentage change (SE) from baseline were assessed for all post-baseline visits, except the post-treatment follow-up visit at Week 56 wherein only mean change from baseline was calculated. TDD was determined using the midpoint of the highest and lowest patient-recorded insulin dose ranges for each week except for Weeks 2–10, 12–22, and 24–56 during which every insulin dose was recorded. If both basal and bolus daily dose data were available, these were converted into weekly ranges and then combined for analysis. For Weeks 1–2, 10–12, and 22–24, average insulin dose was determined.

Logistic regression models were used where the endpoint was a proportion of those achieving a specified target at Week 52, with adjustment for randomization stratification factors and baseline values. A longitudinal repeated-measures approach using direct likelihood was performed for analyses of variables in terms of change or percent change (using log transformation for the endpoint) from baseline for the dapagliflozin treatment

Accepted Article

groups versus placebo, as described previously.<sup>6</sup> The mixed models included terms for the baseline value, treatment, study week, randomization stratification factor, interaction between study week and treatment, and interaction between study week and baseline value.

For missing data at Week 52, the last observation carried forward method was used. Odds ratios (ORs) based on logistic regression for each endpoint and the 95% confidence intervals (CI) were determined for dapagliflozin versus placebo. The 52-week efficacy analyses were considered exploratory as multiplicity adjustments were not performed. Therefore, p-values were not calculated for treatment group comparisons.

Safety outcomes were assessed using the safety analysis set, which included all participants who had received  $\geq 1$  dose of study medication. Analyses on the safety analysis set are based on actual treatment received. Safety was assessed from treatment initiation to the end of the 28-week long-term extension plus the 30-day post-treatment follow-up period. Data were summarized descriptively and no statistical tests were performed to compare rates between treatment groups.

## Results

### Participants

Of the 813 participants randomized in the study, 717 (88.2%) completed the 24-week study and entered the 28-week extension (**Supplementary Figure 1**). In the full analysis set, 231 (85.2%), 226 (83.7%), and 216 (79.4%) participants receiving dapagliflozin 5 mg, 10 mg, and placebo completed the 52-week treatment period, respectively. Baseline characteristics and demographics for all randomized participants have been reported previously (**Supplementary Table 1**).<sup>8</sup>

### Efficacy outcomes

Treatment with dapagliflozin 5 or 10 mg was associated with a reduction in HbA<sub>1c</sub> over 52 weeks, with a similar decrease observed in both groups (**Figure 1A**). Adjusted mean change in HbA<sub>1c</sub> (SE) from baseline to Week 52 was  $-0.11\%$  (0.05) for dapagliflozin 5 mg,  $-0.16\%$  (0.05) for dapagliflozin 10 mg, and  $0.09\%$  (0.05) for placebo. The difference (95% CI) versus placebo was  $-0.20\%$  ( $-0.34, -0.06$ ) and  $-0.25\%$  ( $-0.38, -0.11$ ) for dapagliflozin 5 and 10 mg, respectively.

In patients treated with dapagliflozin 5 and 10 mg, an initial decrease in TDD was observed during the 24-week treatment period, with values remaining lower compared with placebo over the 28-week extension (**Figure 1B**).

Accepted Article

Reductions in body weight observed in both dapagliflozin treatment groups at 24 weeks were sustained over the 52-week treatment period (**Figure 1C**). At Week 52, mean (SD) body weight was 76.0 kg (16.5), 76.6 kg (18.5), and 78.6 kg (18.1) in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively. Adjusted mean percent change in body weight (SE) from baseline to Week 52 was  $-3.67\%$  (0.28),  $-4.11\%$  (0.28), and  $0.78\%$  (0.30) for dapagliflozin 5 mg, 10 mg, and placebo, respectively (difference [95% CI] vs. placebo, dapagliflozin 5 mg:  $-4.42\%$  [ $-5.19$ ,  $-3.64$ ]; and dapagliflozin 10 mg:  $-4.86\%$  [ $-5.63$ ,  $-4.08$ ]; **Figure 1C**).

The proportion of participants achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$  after 52 weeks was higher in participants receiving dapagliflozin 5 or 10 mg compared with those receiving placebo (35.3, 35.2, and 22.3, respectively; **Figure 1D**). The OR (95% CI) versus placebo for achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$  was 1.92 (1.29, 2.84) and 1.95 (1.32, 2.89) for dapagliflozin 5 and 10 mg, respectively. The proportion of participants achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$  without a severe hypoglycemia event after 52 weeks was higher in the dapagliflozin 5 and 10 mg groups compared with placebo (32.7%, 32.2%, and 20.8%, respectively; **Figure 1E**). The OR (95% CI) versus placebo for achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$  without experiencing severe hypoglycemia was the same for both dapagliflozin 5 and 10 mg doses (1.85 [1.24, 2.77]).

At Week 52, reductions in FPG were observed in the dapagliflozin 5 and 10 mg groups compared with placebo, with a difference versus placebo (95% CI) of  $-1.14$  mmol/L ( $-1.85, -0.43$ ) and  $-1.04$  mmol/L ( $-1.76, -0.32$ ) for dapagliflozin 5 and 10 mg, respectively (**Supplementary Table 2**).

Among participants having hypertension at baseline, there was a numerical reduction in SBP in the dapagliflozin treatment groups compared with the placebo group at Week 52, although the 95% CIs included zero for the higher dose of dapagliflozin with a difference versus placebo (95% CI) of  $-6.76$  mmHg ( $-12.93, -0.58$ ) and  $-3.34$  mmHg ( $-10.06, 3.38$ ) for dapagliflozin 5 and 10 mg, respectively (**Supplementary Table 3**).

### **Safety outcomes**

The proportion of participants with at least one AE over the 52-week treatment period plus 30-day follow-up was similar in the dapagliflozin 5 mg, 10 mg, and placebo groups (82.3%, 75.9%, and 75.4%, respectively; **Table 1**). AEs leading to study discontinuation occurred in 8.9%, 6.3%, and 6.6% of participants in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively (**Table 1**). The most frequently reported AEs ( $\geq 5\%$  in any treatment group) by preferred term are shown in **Supplementary Table 4**, and included nasopharyngitis (21.0%, 23.3%, and 25.4%), upper respiratory tract infection (9.6%, 6.3%, and 5.5%), pollakisuria (8.1%, 5.2%, and 2.6%), and headache (6.3%, 6.7%, and 4.8%) in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively.

The proportion of participants with at least one SAE was higher in the dapagliflozin treatment groups versus placebo (**Table 1**). The summary of observed SAEs is presented in **Supplementary Table 5**. AESIs are shown in **Table 1**. Genital infections were the most common AESI, with vulvovaginal mycotic infections observed in 10 (3.7%), 12 (4.4%), and 5 (1.8%), and fungal genital infections in 6 (2.2%), 7 (2.6%), and 0 participants in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively. The second most common AESI was hypersensitivity, which was observed in 10.0%, 6.7%, and 7.7% of participants in the dapagliflozin 5 mg, 10 mg and placebo groups, respectively, most of which were skin-related AEs such as rash and dermatitis.

A summary of hypoglycemic events observed in the dapagliflozin and placebo groups is provided in **Table 2**. Severe hypoglycemia was uncommon, with a similar number of participants in the dapagliflozin 5 mg, 10 mg, and placebo groups experiencing an event (**Table 2**); SAEs of hypoglycemia were rare in all treatment groups (**Table 1**). Very few participants in any treatment group experienced SAEs of hypoglycemia leading to study discontinuation (**Table 1**).

The proportion of participants with an event adjudicated as definite DKA was higher in both the dapagliflozin 5 and 10 mg groups than in the placebo group (4.1%, 3.7%, and 0.4%, respectively; **Table 3**). There was a higher incidence of events adjudicated as definite DKA in continuous subcutaneous insulin infusion vs. multiple daily injection



users in any treatment group (16 [5.8%] versus 6 [1.1%], respectively). There was no difference in the proportion of participants with an event adjudicated as definite DKA in any treatment group when stratified by baseline HbA<sub>1c</sub> <9.0% and ≥9.0% (17 [2.7%] and 5 [2.8%], respectively). The majority of events adjudicated as definite DKA were either mild or moderate in severity. The most common identified primary causes of events adjudicated as definite DKA in the dapagliflozin treatment groups were insulin pump failure or missed insulin dose. All DKA events resolved with treatment.

There were no notable differences in laboratory parameters from baseline to Week 52 among the three treatment groups, with the exception of an expected increase in urinary glucose in the dapagliflozin treatment groups (data not shown). There were no notable differences in vital signs and electrocardiogram data among the three treatment groups (data not shown).

## **Discussion**

In this long-term extension of the DEPICT-2 study, dapagliflozin as an adjunct to insulin was associated with a reduction in HbA<sub>1c</sub> over 52 weeks of randomized treatment. The overall efficacy and safety profile of dapagliflozin observed in this study was similar to that seen in the DEPICT-1 52-week study.<sup>6</sup> As the study population in the present study

included a high number of Japanese people in addition to those of European descent, these results support the long-term benefit of dapagliflozin in people with T1D of different ethnicities and countries of origin.

Reduction in HbA<sub>1c</sub> was less pronounced at Week 52 compared with Week 24.<sup>8</sup> The sustainability of the glycemic response of SGLT2 inhibitors over time needs further exploration in real world studies, but the unmasking of the change from baseline in HbA<sub>1c</sub> after the first 24 weeks in this study may have impacted the results observed at Week 52.

Weight management in people with T1D is important as intensive insulin therapy commonly results in weight gain.<sup>12</sup> SGLT2 inhibitors are often associated with weight loss in people with T1D due to a reduction in fat mass related to caloric loss from increased urinary glucose excretion (UGE).<sup>13,14</sup> Consistent with these findings, and in addition to the benefit of HbA<sub>1c</sub> reduction, treatment with dapagliflozin resulted in weight loss of ~4% after 24 weeks that was maintained up to 52 weeks.

Fear of hypoglycemia can be a barrier to treatment intensification in T1D.<sup>15,16</sup> Intensification of insulin therapy and introduction of adjunct therapies are often associated with an increased risk of hypoglycemia.<sup>17,18</sup> In the present study, consistent with findings in the DEPICT-1 52-week study,<sup>6</sup> the proportion of participants experiencing severe hypoglycemia was low in all treatment groups and did not increase in those receiving dapagliflozin versus placebo, despite the improvement in HbA<sub>1c</sub> seen

with dapagliflozin treatment. This may be partly due to the reduction in TDD afforded by the insulin-independent mode of action of dapagliflozin, where the increase in UGE is dependent on blood glucose concentration.<sup>19</sup> Dapagliflozin can reduce the magnitude of plasma glucose fluctuations, with a low intrinsic potential for hypoglycemia. This was supported by CGM data obtained in the DEPICT trials, where no notable differences were observed at Week 24 with regards to the percentage of glucose values within the ranges indicating hypoglycemia ( $\leq 3.9$  mmol/L [ $\leq 70$  mg/dL] or  $\leq 3.0$  mmol/L [ $\leq 54$  mg/dL]) over 24 hours in people who received dapagliflozin compared with placebo.<sup>20</sup> The consensus recommendation from the Advanced Technologies & Treatments for Diabetes expert panel states that CGM data should be considered in conjunction with HbA<sub>1c</sub> for the assessment of glycemic status and therapy adjustment for people with T1D.<sup>21,22</sup>

The risk of DKA has been shown to increase with the use of SGLT1/2 and SGLT2 inhibitors in people with T1D.<sup>23,24</sup> As a key clinical strategy, healthcare providers and people with T1D should be educated regarding the symptoms and risks, and provided with appropriate support before the initiation of SGLT2 inhibitors to help recognize and manage DKA.<sup>13,22</sup> The importance of ketone monitoring and appropriate reductions in insulin dose need further attention in current diabetes practice to mitigate DKA risk.<sup>25</sup> Interventions such as the STOP DKA protocol could be useful to prevent DKA if ketone levels rise.<sup>26</sup> In the present study, there was an increase in events adjudicated as

Accepted Article

definite DKA in those receiving dapagliflozin at 52 weeks (4.1%, 3.7% and 0.4% for dapagliflozin 5 mg, 10 mg, and placebo, respectively) compared with definite DKA events at 24 weeks (2.6 and 2.2% for dapagliflozin 5 mg and 10 mg vs. 0% for placebo, respectively).<sup>6</sup> The risk of DKA appeared to be constant between the first 24 weeks and the 28-week extension of DEPICT-2, so the risk did not diminish over time. Consistent with the DEPICT-1 study, all DKA events resolved with treatment.<sup>6,7</sup>

The DEPICT-1 and -2 studies featured education on how to recognize symptoms of DKA, and guidance for patients to contact the investigators if ketones were even mildly elevated applied across both clinical teams and study participants. Despite these initiatives, the risk of DKA remained higher in those receiving dapagliflozin versus placebo. As outlined in the European Summary of Product Characteristics for dapagliflozin, patients with T1D should be evaluated for their DKA risk and educated on how to recognize signs and symptoms before initiating dapagliflozin; in cases where DKA is suspected or diagnosed, dapagliflozin treatment should be stopped immediately.<sup>2</sup>

The use of SGLT1/2 and SGLT2 inhibitors in clinical practice must be evaluated against the background of increased DKA risk, emphasizing the need for careful patient selection and education by the prescribing physician to optimize treatment benefits and minimize the risk of DKA. Patients most likely to display a positive benefit/risk profile with dapagliflozin treatment include those with a BMI  $\geq 27$  kg/m<sup>2</sup>; those with low DKA risk

profiles who utilize relevant education relating to DKA risk mitigation strategies; those who are receiving established, stable, and optimized insulin therapy, with insulin doses of >0.5 units/kg body weight/day; and those who do not use insulin pumps.<sup>25,27</sup>

Our results also add to data already reported for other SGLT1/2 and SGLT2 inhibitors in T1D therapy. Changes in HbA<sub>1c</sub>, TDD, and body weight observed in the present study were consistent with those reported for the two higher doses of empagliflozin (10 and 25 mg) in the EASE Phase 3 program<sup>28</sup> and for sotagliflozin in the inTandem1 and 2 studies.<sup>29,30</sup> Although improvements in glycemic control and weight loss without an increase in the risk of hypoglycemia have been associated with dapagliflozin<sup>24</sup>, an increased risk of DKA that does not appear to diminish over time has also been observed.<sup>31</sup> The benefit/risk profile of dapagliflozin in the treatment of T1D should be evaluated further in real-world settings to determine whether the numerical attenuation seen in HbA<sub>1c</sub> over time is present outside the clinical trial setting and to improve understanding of how to mitigate the risk of DKA in clinical practice.

The present study has some limitations. Firstly, insulin was not titrated using a protocol-mandated algorithm, which may have masked the full glycemic potential of dapagliflozin. Secondly, the way in which insulin dose was captured and analyzed differed in the short-term and long-term periods, making comparisons between treatment groups throughout the 52 weeks difficult. Finally, people with certain

comorbidities such as unstable or rapidly progressing renal disease were excluded, which may affect applicability to some populations.

## **Conclusion**

Dapagliflozin as an add-on to adjustable insulin in people with T1D demonstrated long-term reductions in HbA<sub>1c</sub> and sustained weight loss. Dapagliflozin was well-tolerated in this geographically diverse population, with no increased risk of hypoglycemia. These findings are consistent with those from previous long-term studies of SGLT2 inhibitors in people with T1D and in those with T2D. Although dapagliflozin was associated with increased DKA, this risk was manageable and all events resolved with treatment. It is important that the risk of DKA is considered when treating adults with T1D with dapagliflozin, and that risk mitigation strategies are implemented, including active patient selection and education.

## **Acknowledgements**

The authors thank the participating adults, their families, and all investigators involved in this study. Medical writing support was provided by Jonathon Ackroyd, inScience Communications, Springer Healthcare, and was funded by AstraZeneca.

## Data availability

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at

<https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure>

## Funding

This study was funded by AstraZeneca and Bristol-Myers Squibb.

## Disclosures

C.M. has served as a consultant or advisory board member for ActoBio Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp and Dohme Ltd., Novo Nordisk, Roche, and Sanofi and has also received honorarium from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Novo Nordisk, and Sanofi. G.R. received honorarium for conducting this clinical trial, as well as from AstraZeneca, Eli Lilly, Novo Nordisk, and Merck Sharp and Dohme, and participated in advisory boards for Merck Sharp and Dohme, AstraZeneca, Eli Lilly, and Novo Nordisk.

E.A. has participated on advisory panels for Alcon, Astellas Pharma, AstraZeneca, Eli Lilly, Kowa Pharmaceutical, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Sanofi, and Terumo Corporation, has received honoraria for lectures from Astellas Pharma, MSD, Ono Pharmaceutical, Novo Nordisk Pharma, and Sanofi, and

Accepted Article

scholarship grants from Astellas Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanofi, Shionogi, Sumitomo Dainippon Pharma, and Takeda Pharmaceutical. M.L. has received research grants from AstraZeneca, DexCom, Novo Nordisk, and Pfizer, has been a consultant for or received honoraria from AstraZeneca, DexCom, Eli Lilly, Medtronic, MSD, Novo Nordisk, and Rubin Medical. P.D. serves on the advisory boards of AstraZeneca, Novo Nordisk, Sanofi, Boehringer Ingelheim, Merck Intarcia, and AbbVie and has received research grants from all of these companies, apart from Intarcia. M.P. serves on the advisory boards of Sanofi, Medtronic, Novo Nordisk, Eli Lilly, and Pfizer, has received research grants from Medtronic, Novo Nordisk, Roche, Eli Lilly, Merck, Sanofi, Pfizer, Bristol-Myers Squibb, OPKO, Dexcom, Insulet and Lexicon, and honorarium, consultation and speaker bureau from Sanofi, Medtronic, Novo Nordisk, Eli Lilly, Pfizer, RSP Systems, Qulab Medical, AstraZeneca, Lilly, and Insulet. In addition, M.P. is a stockholder for DreaMed Diabetes, NG Solutions, and NutriTeen Professionals. N.A., N.I., and F.T. are employees of AstraZeneca. M.F.S. is an employee of Bayer. At the time of the study, M.F.S. was an employee of AstraZeneca. No other conflicts of interest relevant to this article were reported.



## Author contributions

C.M., P.D., E.A., M.P., N.A., F.T., and M.L. contributed to the study concept and design, analysis and interpretation of the study data. G.R., C.M., E.A., M.L., P.D., N.A., N.I., M.S., M.P., and F.T. contributed to the drafting of the manuscript and critical revision for intellectual content. C.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

## Prior presentation

This study was presented at the 18<sup>th</sup> International Congress of Endocrinology (ICE) Congress, 01–04 December 2018, Cape Town, South Africa and the European Association for the Study of Diabetes, 55<sup>th</sup> Annual Meeting, 16–20 September 2019, Barcelona, Spain. *Post hoc* analyses of DEPICT-2 have been presented as abstracts at American Diabetes Association's (ADA) 79<sup>th</sup> Scientific Sessions, June 7–11, 2019, San Francisco, California.

## References

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes Care*. 2014;37(7):2034-2054.
2. EMC. Forxiga 5 mg film-coated tablets: European Summary of Product Characteristics. <https://www.medicines.org.uk/emc/product/2865/smpc>. Accessed 28 August 2019.
3. Japanese Ministry of Health Labour and Welfare. Forxiga 5 and 10 mg product label. 2019; [https://www.info.pmda.go.jp/go/pack/3969019F1027\\_2\\_10/?view=frame&style=XML&lang=ja](https://www.info.pmda.go.jp/go/pack/3969019F1027_2_10/?view=frame&style=XML&lang=ja). Accessed 20 Dec 2019.
4. Araki E, Watada H, Uchigata Y, et al. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. *Diabetes, obesity & metabolism*. 2019;10.1111/dom.13922.
5. New add-on treatment to insulin for treatment of certain patients with type 1 diabetes. [press release]. 2019.
6. Dandona P, Mathieu C, Phillip M, et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. *Diabetes Care*. 2018;41(12):2552-2559.
7. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a

multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2017;5(11):864-876.

8. Mathieu C, Dandona P, Gillard P, et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. *Diabetes Care.* 2018;41(9):1938-1946.
9. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. *Diabetes Care.* 2013:DC\_122480.
10. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. *Diabetes Care.* 2011;34(6):e61-e99.
11. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic Crises in Adult Patients With Diabetes. *Diabetes Care.* 2009;32(7):1335-1343.
12. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes--causes, effects and coping strategies. *Diabetes Obes Metab.* 2007;9(6):799-812.
13. Riddle MC, Cefalu WT. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True? *Diabetes Care.* 2018;41(12):2444-2447.
14. Li K, Xu G. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials. *J Diabetes.* 2019;11(8):645-655.
15. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. *Diabetes Care.* 2010;33(6):1389-1394.

- Accepted Article
16. Cryer PE, Davis SN, Shamon H. Hypoglycemia in Diabetes. *Diabetes Care*. 2003;26(6):1902-1912.
  17. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. *Diabetes Care*. 2016;39(10):1702-1710.
  18. Ahren B, Hirsch IB, Pieber TR, et al. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. *Diabetes Care*. 2016;39(10):1693-1701.
  19. Henry RR, Strange P, Zhou R, et al. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes technology & therapeutics*. 2018;20(11):715-724.
  20. Mathieu C, Dandona P, Phillip M, et al. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. *Diabetes Care*. 2019;42(6):1081-1087.
  21. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019.
  22. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*. 2017;40(12):1631-1640.
  23. Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. *BMJ (Clinical research ed)*. 2019;365:l1328.

24. McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. *Diabetologia*. 2018;61(10):2126-2133.
25. Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes. *Diabetes Ther*. 2020;11(1):37-52.
26. Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. *Diabetes, Obesity and Metabolism*. 2019;21(10):2192-2202.
27. Yanai H, Adachi H, Hakoshima M, Katsuyama H. An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors. *Journal of clinical medicine research*. 2019;11(1):76-79.
28. Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. *Diabetes Care*. 2018;41(12):2560-2569.
29. Danne T, Cariou B, Banks P, et al. HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. *Diabetes Care*. 2018;41(9):1981-1990.
30. Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. *Diabetes Care*. 2018;41(9):1970-1980.
31. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. *Diabetes Obes Metab*. 2018;20(3):620-628.

## Figures

**Figure 1. (A) Change in HbA<sub>1c</sub> (%) over 52 weeks; (B) Change in TDD (%) over 52 weeks; (C) Change in total body weight (%) over 52 weeks; (D) Proportion of participants achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$ ; (E) Proportion of participants achieving an HbA<sub>1c</sub> reduction of  $\geq 0.5\%$  without severe hypoglycemia (%) over 52 weeks.**


Week 0–52 data show adjusted mean change from baseline (SE); Week 56 data are only mean change from baseline. Data are for all participants in the full analysis set. The study's primary and secondary endpoints were assessed in the 24-week treatment period (indicated by a black line at Week 24), and exploratory endpoints were assessed at Week 52 in the long-term 28-week extension.

HbA<sub>1c</sub> (%): mean (SD) at baseline was 8.44 (0.69), 8.42 (0.69), and 8.41 (0.64) for dapagliflozin 5 mg, 10 mg and placebo, respectively. Body weight (%): mean (SD) at baseline was 78.7 kg (17.4), 80.1 kg (18.3), and 78.9 kg (18.9) for dapagliflozin 5 mg, 10 mg and placebo, respectively. TDD, U (SD) at baseline was 58.19 (27.93), 58.68 (28.26) and 56.57 (25.23) for dapagliflozin 5 mg, 10 mg, and placebo, respectively.

SE, standard error; SD, standard deviation; TDD, total daily insulin dose.

Figure 1.

A.




Patients per timepoint

Dapagliflozin 5 mg	267	265	258	253	250	247	234	234	221	225	241
Dapagliflozin 10 mg	268	265	261	258	246	245	237	232	217	218	241
Placebo	267	265	260	258	246	240	225	222	214	212	230

B.

○ Dapagliflozin 5 mg + insulin (N=271) ● Dapagliflozin 10 mg + insulin (N=270) □ Placebo + insulin (N=272)




Patients per timepoint

Dapagliflozin 5 mg	270	266	267	263	255	259	254	250	251	250	249
Dapagliflozin 10 mg	269	263	269	265	256	257	247	249	250	243	245
Placebo	271	263	266	265	256	254	241	238	235	232	230




C.



Patients per timepoint	0	2	4	8	12	18	24	32	40	48	52	56
Dapagliflozin 5 mg	269	265	259	256	250	247	236	235	224	227	244	
Dapagliflozin 10 mg	269	266	261	259	248	246	237	233	219	220	243	
Placebo	272	265	261	258	246	241	228	224	216	212	232	

D.



F.




Table 1. Safety summary.

	Dapagliflozin 5 mg + insulin (N=271)	Dapagliflozin 10 mg + insulin (N=270)	Placebo + insulin (N=272)
<b>AEs</b>			
≥1 AE	223 (82.3)	205 (75.9)	205 (75.4)
≥1 AE related to the study drug	88 (32.5)	83 (30.7)	49 (18.0)
AE leading to discontinuation of study drug	24 (8.9)	17 (6.3)	18 (6.6)
<b>AESI*</b>			
Genital infection	30 (11.1)	28 (10.4)	10 (3.7)
Hypersensitivity	27 (10.0)	18 (6.7)	21 (7.7)
Urinary tract infection	25 (9.2)	14 (5.2)	18 (6.6)
Hypotension/Dehydration/ Hypovolemia	10 (3.7)	3 (1.1)	5 (1.8)
Fractures	8 (3.0)	5 (1.9)	4 (1.5)
Renal impairment/failure	3 (1.1)	1 (0.4)	1 (0.4)
Cardiovascular events	1 (0.4)	3 (1.1)	3 (1.1)
<b>SAEs</b>			
≥1 SAEs	32 (11.8)	19 (7.0)	16 (5.9)
≥1 SAEs related to the study drug	15 (5.5)	7 (2.6)	4 (1.5)
SAEs leading to discontinuation of study drug	17 (6.3)	5 (1.9)	6 (2.2)
<b>Death</b>	1 (0.4) <sup>†</sup>	0	0
<b>Hypoglycemia</b>			
≥1 SAE of hypoglycemia	5 (1.8)	1 (0.4)	2 (0.7)
SAE of hypoglycemia leading to discontinuation of study drug	2 (0.7)	1 (0.4)	1 (0.4)

### Ketone-related events

≥1 ketone related SAEs	15 (5.5)	7 (2.6)	1 (0.4)
Ketone-related SAE leading to discontinuation of study drug	12 (4.4)	4 (1.5)	0

---

All data are n (%). Safety was assessed over 52 weeks of treatment plus 30-days post-

treatment. \*The total number of participants with an event, organized by system organ class;

†One death in the dapagliflozin 5 mg group was due to an SAE that was not related to the study treatment. AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event.

**Table 2. Summary of hypoglycemic events.**

	Dapagliflozin 5 mg + insulin (N=271) [246.0 patient-years]	Dapagliflozin 10 mg + insulin (N=270) [246.3 patient-years]	Placebo + insulin (N=272) [239.6 patient-years]
Total number of hypoglycemic events, n	7998	8321	8054
Participants with $\geq 1$ event, n (%)	231 (85.2)	234 (86.7)	237 (87.1)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	3251.27	3378.74	3361.82
Severe hypoglycemia			
Number of events, n	97	84	65
Number of participants with $\geq 1$ event, n (%)	24 (8.9)	26 (9.6)	23 (8.5)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	39.43	34.11	27.13
Documented symptomatic hypoglycemia			
Number of events, n	6121	6494	6228
Number of participants with $\geq 1$ event, n (%)	225 (83.0)	221 (81.9)	229 (84.2)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	2488.25	2636.89	2599.63

## Asymptomatic hypoglycemia

Number of events, n	1487	1564	1548
Number of participants with $\geq 1$ event, n (%)	108 (39.9)	138 (51.1)	114 (41.9)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	604.48	635.06	646.15

## Probable symptomatic hypoglycemia

Number of events, n	119	105	125
Number of participants with $\geq 1$ event, n (%)	23 (8.5)	37 (13.7)	25 (9.2)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	48.37	42.64	52.18

## Relative hypoglycemia

Number of events, n	119	64	82
Number of participants with $\geq 1$ event, n (%)	24 (8.9)	21 (7.8)	32 (11.8)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	48.37	25.99	34.23

## Other hypoglycemia

Number of events, n	55	10	6
Number of participants with $\geq 1$ event, n (%)	8 (3.0)	7 (2.6)	5 (1.8)
Exposure-adjusted incidence rate, per 100 patient-years including recurrences	22.36	4.06	2.50

---

Safety was assessed over 52 weeks of treatment plus 30-days post-treatment. All reported hypoglycemic events with onset within four days of last day of treatment are included.

Hypoglycemia categorization is based on the ADA classifications.



**Table 3. Summary of events adjudicated as diabetic ketoacidosis.**

	Dapagliflozin 5 mg + insulin (N=271)	Dapagliflozin 10 mg + insulin (N=270)	Placebo + insulin (N=272)
Participants with events sent for adjudication, n (%)	27 (10.0)	23 (8.5)	11 (4.0)
Participants with definite DKA, n (%)	11 (4.1)	10 (3.7)	1 (0.4)
Number of events of definite DKA, n	11	10	1
Incidence rate, per 100 patient-years	4.47	4.06	0.42
Severity of event as adjudicated, n (%) <sup>†</sup>			
Mild	4 (36.4)	4 (40.0)	0
Moderate	5 (45.5)	4 (40.0)	1 (100.0)
Severe	2 (18.2)	2 (20.0)	0
Number of events of euglycemic DKA, n <sup>‡</sup>	3	2	0
Primary cause of definite DKA events, n (%) <sup>†</sup>			
Insulin pump failure	1 (9.1)	3 (30.0)	0
Missed insulin dose	4 (36.4)	1 (10.0)	0
Severe illness	1 (9.1)	1 (10.0)	0
Not identified	4 (36.4)	1 (10.0)	1 (100.0)
Other	1 (9.1)	4 (40.0)	0
Mean percent TDD reduction compared to	-17.35	-19.49	-4.19

baseline for week  
before definite DKA  
events, %

Mean percent TDD reduction compared with baseline at end of treatment period in participants with definite DKA events, %	-12.26	-23.00	5.13
---	--------	--------	------

Events adjudicated as  
not DKA

Participants with possible DKA, n (%)	8 (3.0)	4 (1.5)	2 (0.7)
Number of events of possible DKA, n	9	4	2
Participants with unlikely DKA, n (%)	10 (3.7)	10 (3.7)	9 (3.3)
Number of events of unlikely DKA, n	20	27	21

---

Safety was assessed over 52 weeks of treatment plus 30-days post-treatment. <sup>†</sup>Percentages are based on total number of events of definite DKA in each treatment group. <sup>‡</sup>Based on patient's own meter reading.

DKA, diabetic ketoacidosis; SAEs, serious adverse events